However, despite the significant AngII level reduction accompanied by the rapid upregulation of RAS peptides Ang-(1-7) and Ang-(1-5), no significant impact in the alleviation of the clinical severity of ARDS has been observed, with no difference in PaO2/FiO2 (partial pressure of arterial oxygen to fraction of inspired oxygen) ratio between treatment groups and placebo [106]. The gene discussed is ANG; the disease is acute respiratory distress syndrome.